Cancer Causes & Control

, Volume 22, Issue 3, pp 523–527 | Cite as

Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers

  • Hitoshi Tajiri
  • Hideo Tanaka
  • Stephen Brooks
  • Tomoko Takano
Brief report



A nation-wide prevention program utilizing passive-active immunoprophylaxis for high-risk babies against maternal HBV transmission was introduced in Japan in January of 1986. The prevention program was expected to eradicate HBV-related hepatocellular carcinoma (HCC). The aim of this study was to evaluate the effect of this selective prevention program against maternal HBV transmission on the occurrence of HBV-related HCC.


We reviewed the annual reports from a nation-wide survey of childhood solid tumors that was reported in the Journal of the Japanese Society of Pediatric Surgeons during the 28 years period from 1981 to 2008. The number of HCC cases were grouped for every 5-year period with an additional period of the past 3 years and compared with those of hepatoblastoma.


The reported number of children with hepatoblastoma in each period was constant during the 28 years study period. In contrast, both the number of patients with HBV-related HCC and the ratio of HBV-related HCC to hepatoblastoma gradually decreased over the study period, with a significant drop in the last two periods ranging from 2001 to 2008 (p < 0.001).


The prevention program against maternal HBV infection of infants born to HBV carrier mothers may have decreased the occurrence of HBV-related HCC in childhood.


Hepatocellular carcinoma Hepatitis B virus Selective vaccination Maternal transmission 


  1. 1.
    Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J (2005) Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100:1995–2004CrossRefPubMedGoogle Scholar
  2. 2.
    Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY (1989) Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 64:2377–2380CrossRefPubMedGoogle Scholar
  3. 3.
    Koyama T, Matsuda I, Sato S, Yoshizawa H (2003) Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy. Hepatol Res 26:287–292CrossRefPubMedGoogle Scholar
  4. 4.
    Tanimura M, Matsui I, Abe J et al (1998) Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res 58:3032–3035PubMedGoogle Scholar
  5. 5.
    Mann JR, Kasthuri N, Raafat F et al (1990) Malignant hepatic tumors in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol 4:276–289CrossRefPubMedGoogle Scholar
  6. 6.
    Matsuda T, Marugame T, Kamo K et al (2009) Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 39:850–858CrossRefPubMedGoogle Scholar
  7. 7.
    Ramsay M, Gay N, Balogun K, Collins M (1998) Control of hepatitis B in the United Kingdom. Vaccine 16 Suppl:S52–S55CrossRefPubMedGoogle Scholar
  8. 8.
    Noto H, Terao T, Ryou S et al (2003) Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980–1994. J Gastroenterol Hepatol 18:943–949CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshikawa A, Suzuki K, Abe A et al (2009) Effect of selective vaccination on a decrease in the rate of hepatitis B virus-positive Japanese first-time blood donors. Transfus Med 19:172–179CrossRefPubMedGoogle Scholar
  10. 10.
    Chang MH, Chen CJ, Lai MS et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N Engl J Med 336:1855–1859CrossRefPubMedGoogle Scholar
  11. 11.
    Chang MH, Shau WY, Chen CJ et al (2000) Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284:3040–3042CrossRefPubMedGoogle Scholar
  12. 12.
    Chang MH, You SL, Chen CJ et al (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20 year follow-up study. J Natl Cancer Inst 101:1348–1355CrossRefPubMedGoogle Scholar
  13. 13.
    Chang MH, Chen TH, Hsu HM et al (2005) Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 11:7953–7957CrossRefPubMedGoogle Scholar
  14. 14.
    Lack EE, Neave C, Vawter GF (1982) Hepatoblastoma. A clinical and pathologic study of 54 cases. Am J Surg Pathol 6:693–705CrossRefPubMedGoogle Scholar
  15. 15.
    Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (japanese study group for pediatric liver tumor) protocol-1: a report from the Japanese study group for pediatric liver tumor. J Pediatr Surg 37:851–856CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Hitoshi Tajiri
    • 1
  • Hideo Tanaka
    • 2
  • Stephen Brooks
    • 3
  • Tomoko Takano
    • 1
  1. 1.Department of PaediatricsOsaka General Medical CenterSumiyoshi-kuJapan
  2. 2.Division of Epidemiology and PreventionAichi Cancer Center Research InstituteNagoyaJapan
  3. 3.Department of Microbiology/ImmunologyState University of New York at BuffaloBuffaloUSA

Personalised recommendations